Objective: To evaluate the feasibility, safety, and effectiveness of a novel, absorbable atrial septal defect (ASD) closure device made of poly-L-lactic acid (PLLA) in a swine model of ASD and for the first time in humans.
including the Biodisk and Double Biodisc devices. 8, 10, 11 The BioSTAR device was the first partially bioresorbable occluder approved for ASD and PFO closure in humans. 9, 12, 13 It consists of a metallic permanent double-umbrella framework (MP35N) and a bioresorbable membrane made from acellular porcine intestinal collagen. 9 Early and late complications reported in clinical studies were considered to be attributable to the biological material and immunological properties of the device. 14 Although the BioSTAR device was withdrawn from the market, it has inspired new ideas for the future development of biodegradable devices.
The use of completely bioresorbable septal defect occlusion devices in an experimental setting has been reported, including the "Chinese lantern" device, which is made of fully biodegradable polymers, 15 the polydioxanone/poly (L-lactic acid) (PLLA) 16 device, the PLLA/poly (D, L-lactic acid) (PDLLA) 17 device, and the Carag bioresorbable septal occluder (Carag AG, Baar, Switzerland), which consists of a framework made of a poly(lactic-co-glycolic acid) monofilament. 18 In addition, Liu et al 19 introduced a novel biodegradable occlusion device made of poly(ε-caprolactone) (PCL) and poly-D-Llactide-glycolide (PLGA)/collagen nanofibers. in vitro studies have shown that the PCL device with a PLGA/collagen nanofibrous membrane had comparable mechanical properties to that of commercial metallic occluders. Although the effectiveness and safety of these new devices have been confirmed in animal models, the feasibility and safety in humans remain to be determined.
The 12-month outcomes of our previous preclinical studies demonstrated that the implanted PLLA biodegradable device achieved good endothelialization and degradability in short and moderate term follow-ups in a swine model of ASD. 20, 21 In the present article, we report the 24-and 36-month follow-up results of PLLA device implantation in an animal model and describe the first human experience with the PLLA device for ASD closure in a consecutive series of patients by focusing on the feasibility and preliminary efficacy at 6 months.
| METHODS AND MATERIALS

| Device description
The PLLA device is a biodegradable ASD closure device with a selfexpandable, double-disc framework made of 0.006-in. (0.15 mm) PLLA wire meshes ( Figure 1 ). PLLA membranes are sewn onto the two discs and the waist with PLLA sutures. The PLLA device has seven platinum-iridium radio-opaque marks, with one at the tip of the left atrial disc, two at both ends of the discs, and two at the waist ( Figure 2 ). A locking system, which is composed of a PLLA stick, is attached to the left disk on one side and coaptated to the delivery system with an angle tip and internal screw on the other. By controlling the locking system, the device can be in the "unlocked" or "locked" state ( Figures 1 and 2 ). The details of the device structure are described in our previous preclinical study. 21 The device is available in various sizes ranging from 6 to 32 mm at 2-mm increments.
The delivery system consists of a delivery cable, a handle, a loader, an assistant loader, and a hemostatic valve ( Figure 3a ). The controlling portion of the handle consists of a locking wheel, a push button, and a device deployment, with one at the starting point, one at the mid position, and one at the end. Before device deployment, the back cover is pulled back and more than 10 counterclockwise rotations are made, followed by counterclockwise rotations of the controlling handle to disconnect the delivery cable from the screw of the device.
The PLLA device is preloaded with the delivery system (Figure 3c) and rehydrated with saline solution before loading into the loader. The animals were followed-up at 1, 3, 6, 12, 24, and 36 months after device implantation. Chest X-ray, TTE, electrocardiography (ECG), and blood tests were performed periodically. Two or three animals from each group were sacrificed at different time points and the hearts, spleens, livers, lungs, and kidneys were removed for pathological examination. Gross anatomical examinations were performed to observe the morphologies of the device and adjacent anatomic structures. The harvested tissues from the implanted devices and atrial septum were subjected to histological analysis to evaluate the surrounding inflammatory response, endothelialization, and degradation of the PLLA wires and membrane. Moreover, scanning electron microscopy and immunohistochemical analysis were selectively performed to observe the process of endothelialization.
| Preclinical study
| CLINICAL STUDY
| Patients and ethical approval
Between May and June 2018, five pediatric patients (four boys and one girl) who were scheduled for percutaneous closure of secundum ASD at our hospital were included in the study. The diagnosis and evaluation of ASD prior to closure was performed by TTE for all patients. Indications for ASD closure were: an ASD ≥5 mm and ≤30 mm in diameter, with sufficient rims of atrial tissue (superior to the coronary sinus, superior/inferior vena cava, and pulmonary vein by 5 mm and superior to the mitral valve by 7 mm), signs of right ventricular volume overload and/or evidence of significant left-to-right shunting (Qp:Qs ≥ 1.5:1). Patients with other congenital or significant cardiac defects, history of ASD repair, or previous left atrial appendage occlusion were excluded from the study.
The study protocol was approved by the Institutional Review Board of our hospital and conducted in accordance with the Declaration of Helsinki. Written informed was obtained from the parents or legal guardians of all patients prior to study participation. 22 For defects with sufficient rims, a device 4 mm larger than the defect size was chosen, while for those with floppy rims or within a floppy interatrial septum, a device 6 mm larger than the defect size was chosen. A delivery sheath (10F to 12F) was positioned into the LUPV. After rehydration with saline solution, the PLLA device was pulled into the loader and fixed in the "locked" state. The loader was introduced into the delivery sheath and the PLLA device was advanced into the LUPV (Figure 4d ). Delivery of the PLLA device was similar to that previously described for the Amplatzer ASD device. 23 The delivery sheath was retracted until the whole device was exposed from within the sheath (Figure 4e ). Under both fluoroscopic and TTE guidance, the device was unlocked, and the left atrial disc, the waist, and part of the right atrial disc were opened using the push button on the handle. The location of the device was appropriately adjusted to ensure the left atrial disk was located at the left side of the atrial septum (Figure 4f With both discs located against the septum and the defect fully covered, the delivery system was activated to release the device ( Figure 4j ,k,l-n).
| Device implantation procedure
| Follow-up
On day 1 after device closure, TTE was performed to evaluate the device position, residual shunts, interference with adjacent structures, valvular function, and pericardial effusion. ECG was also recorded to evaluate cardiac arrhythmia. Follow-up data at 30 days, 3 months, and 6 months after device closure were obtained, including all events and symptoms, as well as the TTE and ECG results. All patients were prescribed aspirin (3-5 mg/kg once daily for 6 months) after closure.
The primary outcomes of interest were procedural success and residual shunts at follow-up, as well as the occurrence of major adverse events, such as sudden cardiac death, cardiac tamponade, device displacement or migration requiring cardiac surgery, cardiac erosion, thromboembolism, and air embolism. Secondary outcomes included new onset of cardiac arrhythmia, significant aortic valve or mitral valve regurgitation, and all-cause mortality. examinations showed that the PLLA device was not identifiable and became an integral part of the septum. Both discs had been totally covered by new endothelial tissue (Figure 6a,b) . In contrast, although both discs of the nitinol device were covered by new endothelial tissue, the metal wires were still clearly visible (Figure 6c ). Hematoxylin-eosin (HE) staining showed that most of the PLLA wires had disintegrated into pieces (Figure 7a ). Large amounts of collagen fibers and fibroblasts were deposited around the PLLA device (Figure 7a,b) . Chronic inflammatory reactions consisted of a few lymphocytes that were loosely distributed in the newly formed tissue, but the inflammatory reactions were weaker as compared to that at the 12-month follow-up.
| Statistical analysis
Similarly, at the 36-month follow-up, TTE demonstrated that the PLLA device was basically invisible, with no residual shunts, valvular insufficiency, or cardiac function impairment (Figure 8 ). Macroscopic examination showed that both discs of the PLLA device were completely substituted by autogenous tissue (Figure 9 ). HE staining showed that there were no clear boundaries between the device skeleton and surrounding tissues, so Masson staining was used to identify the boundary between the new endothelial tissues and atrial septum (Figure 10a,b) . The PLLA device was almost completely degraded, except for a small amount of PLLA from the tip of the device (Figure 10a ). The skeleton of the device was replaced by a layer of thickened tissue that was composed of collagen fibers, fibroblasts, and newly formed vessels (Figure 10c,d) . The presence of endothelial cells was confirmed by immunohistochemical staining of CD31 (Figure 10e ).
There was no evidence of significant inflammatory responses around the thickened tissues, necrosis, or tissue degeneration.
At the 24-and 36-month follow-ups, there were no abnormalities of gross specimens of the lungs, liver, spleen, and kidneys, with no evidence of thrombus formation or infarction.
| Clinical study
A total of five PLLA ASD closure devices were successfully and uneventfully implanted in all five patients. Patient characteristics are outlined in Table 1 . The median age was 3.6 (range, 3.1-6.5) years. On day 1 after device implantation, complete closure of the defect with no residual shunt was achieved in four (80%) of five cases (Table 3) . No major adverse events, such as device dislodgement, thromboembolism, excessive pericardial effusion, or cardiac tamponade, were observed during or after implantation. New trivial mitral regurgitation was detected in three (60%) of the five cases. Sinus rhythm persisted in all of five cases on the day 1 after device implantation.
Follow-up data at 30 days, 3 months, and 6 months were obtained for all five patients (Table 3) PLLA was used as the matrix of our biodegradable device. PLLA is a copolymer of PLA, which is reported to have high tensile strength, good flexibility, and good thermal stability. 24 Due to the biocompatibility and bioresorbability in the human body, PLA polymers have been used in a number of biomedical applications, including implants, drug delivery, and tissue engineering. [25] [26] [27] The reason for choosing a PLLA device 4-6 mm larger than the defect size was mainly based on the principle of metal device selection in the common view of Chinese medical experts regarding interventional ASD treatment. 22 The results of the present study confirmed the feasibility of this method.
Our clinical study showed that one of the five patients (patient no. 1), with a 17-mm ASD and was implanted with a 24-mm PLLA device, exhibited a persistent mild residual shunt during follow-up, while our previous preclinical study results showed that no residual shunt was detected in the experimental group at 1, 3, 6, and 12-month follow-up. 21 The difference between these results may due in part to the different natures of the defects. In a preclinical study, the defects were created by trans-septal puncture and balloon dilation with small sizes ranging from 4 to 7 mm and were centrally located with good margins. A device 3-4 mm larger than the defect size was adequate to achieve complete closure. In a clinical study, larger defects ranging from 10 to 17 mm with floppy rims were included. In addition, during the first clinical procedures, there was a learning curve associated with the deployment technique and identifying the placement of the device under fluoroscopic and TTE guidance. Therefore, although we chose a device that was 7 mm larger than the defect size for patient no. 1, a mild residual shunt still existed, which was hemodynamically insignificant, thus no additional treatment was necessary.
The study results demonstrated some advantages of the PLLA device for closure of small to medium sized defects. First, the reduction in the number of PLLA wires (from 72 to 36) and the size of PLLA membrane makes it possible to deliver the PLLA device in a smaller sheath, which could be a huge benefit to pediatric patients. Second, the seven marks ensures visibility of the device by X-ray. Upon release, each group of the two marks at the left disc, the waist, and the right disc should be parallel, and the mark at the tip and two marks at the left disc should form a triangle. Any malformation or dislocation of the device could be detected by X-ray based on the location of the seven marks during and after the closure procedure. Third, the PLLA device is available in various sizes ranging from 6 to 32 mm at 2-mm increments, which permits its use for the treatment of a wide range of defect sizes from 5 to 28 mm. The PLLA device is greatly improved as compared to other biodegradable devices with configured sizes, such as the BioSTAR and Carag bioresorbable septal occluders, which have been used in clinical studies. Fourth, the PLLA device reserves the possibility of trans-septal puncture in future transcatheter procedures.
In our preclinical study, fracture force was assessed with a tensile test with a strain rate of 10 mm/min in the newborn tissue group (n = 3) and the septum primum group (n = 3). There was no significant difference in the fracture force between the newborn tissue group and the septum primum group (11.07 ± 3.55 vs. 7.07 ± 1.84 N, respectively, p = .181), suggesting that the newborn tissue had similar biomechanical properties as the septum primum group, which makes future transseptal puncture possible.
Compared to metal alloy occluders, the decreased fluoroscopic visibility of the PLLA device may lead to more difficult device retrieval with transcatheter techniques. In our preclinical study, a PLLA device (waist diameter, 20 mm) was intentionally implanted in the "unlocked state" and was embolized into the descending thoracic aorta. A 25-mm goose neck snare was applied to capture the waist of the device in the right femoral artery access. Another 15-mm goose neck snare was introduced to catch the tip of left disc to help stabilize the device in the left femoral artery access. The device was slenderized and pulled into a 14F sheath and successfully retrieved. However, no attempt has been made to retrieve a devise in the "locked state" under fluoroscopic guidance. Based on our experience in vitro, it was harder to retrieve a device in the "locked state" into a same size delivery sheath, as compared to that in the "unlocked state." Therefore, we suggest the use of a sheath larger than the initial delivery sheath to retrieve the embolized device. Moreover, since the marks on the device enable the identification of the position of the waist and the tip of the left disc, the "Waist Capture Technique" 28 with a looped wire or a snare to capture the waist of the device might be feasible for device retrieval.
The PLLA device can achieve excellent results for a small to moderate sized secundum ASD (defect size 10-17 mm), although practical experience is lacking in patients with larger defects. Moreover, the endothelialization and degradation processes of the PLLA device in the human body remain unclear. Hence, further larger prospective clinical trials with long-term follow-up are needed to confirm these favorable preliminary results.
| STUDY LIMITATIONS
There were a few limitations to the present study. The major limitation was the very small cohort of patients from a single institution.
Closure procedures using PLLA devices were performed for only small and moderate sized defects with sufficient rims. The patients were only followed for 6 months, thus the long-term safety of the PLLA devise in humans remains unclear.
| CONCLUSIONS
The results of the present study demonstrated that it is feasible to implant a PLLA device in small to medium sized ASDs without significant residual shunts or severe adverse events in humans. Also, the PLLA device exhibited good endothelialization and degradability at 24-and 36-month follow-ups in a swine model. Studies to evaluate long-term safety and effectiveness of PLLA device in a larger cohort of patients are now warranted.
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